Skip to Main Content

Top of the morning to you, and a fine one, it is. Delicious cool breezes and clear, blue skies are enveloping the Pharmalot campus this morning. One would never know a stubborn pandemic is lurking outside. But it is. And so, we interrupt our usual greeting for a public service announcement: a vaccine is only a shot away. Now back to our regularly scheduled line up of brewing cups of stimulation and foraging for items of interest. And of course, serving up tidbits. Hope your day is productive and, as always, stay safe…

Biogen (BIIB) recently submitted a paper to JAMA that analyzed clinical trial results for its new Alzheimer’s drug, Aduhelm, but later withdrew the paper because the journal considered rejecting it unless edits were made, Axios reports. Biogen says “JAMA did not reject the publication. Biogen withdrew the publication from JAMA and decided to pursue other publication opportunities.” Drug makers almost always publish study results in a peer-reviewed journal before obtaining FDA approval, but Biogen still has not done so for Aduhelm.


Gayle Smith, head of global Covid-19 response at the State Department, urged U.S. vaccine makers to support development of low-cost manufacturing hubs overseas to boost production of cheaper jabs for developing countries, The Financial Times writes. Smith wants the companies to share technological expertise with international rivals that can make vaccines at a lower price point.  “We need to increase the capacity of regions to produce more of the vaccines than they consume,” she said. “Then they can start exporting to countries around them.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.